Cyclo Therapeutics Ended The Quarter With ~$0.8M Of Cash. Subsequent To Quarter-End, The Company Generated Gross Proceeds Of $5M From The Sale Of Securities In Private Placements Of The Co’s Securities
Continued strong enrollment of pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) on track to complete enrollment by year end